A growing body of research is reshaping how scientists understand the relationship between coffee, caffeine, and depression, revealing a complex interaction that may influence both long-term mental health and the effectiveness of advanced depression treatments.
According to the World Health Organization (WHO), 5.7% of adults worldwide — around 332 million people — live with depression. While most respond to standard antidepressant medications, nearly half of all patients experience treatment-resistant depression, requiring advanced therapies such as ketamine and electroconvulsive therapy (ECT).
Psychiatrist Dr Ma-Li Wong, MD, PhD, co-author of Adenosine as the metabolic common path of rapid antidepressant action: The coffee paradox, explains:
“Ketamine and ECT are mainly used when standard antidepressant medications haven’t worked. Almost half of people diagnosed with depression may fall into this category.”
A breakthrough study published in Nature has identified adenosine signaling as the central biological pathway that drives the rapid antidepressant effects of ketamine and ECT.
Adenosine is a naturally occurring signaling molecule responsible for:
Using genetically encoded sensors and mouse models, researchers found that ketamine triggers a rapid, sustained increase in extracellular adenosine within the medial prefrontal cortex and hippocampus—brain regions strongly linked to depression.
When adenosine receptors were blocked or depleted, ketamine’s antidepressant effects disappeared, confirming adenosine’s crucial role.
They also discovered that acute intermittent hypoxia (aIH)—a noninvasive therapy—produced similar antidepressant effects through adenosine signaling.
Dr Wong emphasized:
“The discovery that adenosine signaling drives the antidepressant effects of ketamine and ECT is a big deal. It opens the door to new treatments that act on adenosine, giving us safer and more scalable ways to help people with depression.”
A commentary in Brain Medicine explores the so-called coffee paradox:
Dr Wong warns:
“Caffeine blocks adenosine receptors, and this can interfere with the antidepressant effects of ketamine and ECT—likely in humans as well.”
In habitual coffee drinkers, adenosine receptors become upregulated, which may explain the protective effect against long-term depression.
However, acute caffeine use, especially shortly before treatment, may reduce the effectiveness of ketamine, ECT, or aIH.
Dr Wong recommends avoiding caffeine before treatment:
“It’s sensible to skip coffee or energy drinks for at least 24 hours before ketamine or ECT. Caffeine stays in your system for a long time, and may blunt treatment response.”
However, she notes that more research is needed to determine:
This new evidence highlights several key insights:
As the science evolves, mental health experts encourage patients to speak with their clinicians before making changes to their caffeine habits.
CLICK HERE TO JOIN Medical News Pakistan on WhatsApp for expert tips, health updates, and the latest medical research straight to your phone.